Evaluation of patient immunocompetence for immune checkpoint inhibitor therapy using the psoas muscle index: a retrospective cohort study
IntroductionIn patients with cancer, sarcopenia is an indicator of poor prognosis and is associated with an increased risk of chemotherapy-related adverse events. Skeletal muscle interacts with the immune system, and sarcopenia is associated with immune senescence. However, the association between s...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-02-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2025.1499650/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832087411625033728 |
|---|---|
| author | Toshiaki Tsurui Toshiaki Tsurui Toshiaki Tsurui Toshiaki Tsurui Kazuyuki Hamada Emiko Mura Risako Suzuki Nana Iriguchi Tomoyuki Ishiguro Yuya Hirasawa Ryotaro Ohkuma Masahiro Shimokawa Hirotsugu Ariizumi Yutaro Kubota Atsushi Horiike Satoshi Wada Satoshi Wada Kiyoshi Yoshimura Kiyoshi Yoshimura Mayumi Tsuji Yuji Kiuchi Yuji Kiuchi Takuya Tsunoda |
| author_facet | Toshiaki Tsurui Toshiaki Tsurui Toshiaki Tsurui Toshiaki Tsurui Kazuyuki Hamada Emiko Mura Risako Suzuki Nana Iriguchi Tomoyuki Ishiguro Yuya Hirasawa Ryotaro Ohkuma Masahiro Shimokawa Hirotsugu Ariizumi Yutaro Kubota Atsushi Horiike Satoshi Wada Satoshi Wada Kiyoshi Yoshimura Kiyoshi Yoshimura Mayumi Tsuji Yuji Kiuchi Yuji Kiuchi Takuya Tsunoda |
| author_sort | Toshiaki Tsurui |
| collection | DOAJ |
| description | IntroductionIn patients with cancer, sarcopenia is an indicator of poor prognosis and is associated with an increased risk of chemotherapy-related adverse events. Skeletal muscle interacts with the immune system, and sarcopenia is associated with immune senescence. However, the association between sarcopenia and the response to immune checkpoint inhibitor (ICI) therapy remains unclear.MethodsThis retrospective study included patients with advanced or recurrent non-small cell lung cancer treated with nivolumab or pembrolizumab monotherapy. The association between the psoas muscle index (PMI) and both clinical response and immune-related adverse events (irAEs) was assessed using logistic regression. The PMI was calculated as the cross-sectional area of the psoas muscle divided by the square of the height based on computed tomography scans performed before the initial administration of ICI therapy.ResultsA total of 67 patients were included in the analysis. Logistic regression analysis showed that PMI was associated with the overall response (odds ratio [OR]: 1.52; 95% confidence interval [CI]: 1.04–2.22; p = 0.030) and the risk of severe irAEs (OR: 1.72; 95% CI: 1.05–2.80; p = 0.031).ConclusionThese findings suggest that PMI is both an indicator of prognosis and a surrogate marker of immunocompetence in predicting the clinical response to ICI therapy. |
| format | Article |
| id | doaj-art-aee118fa3adf4ee98dee676326c60b1a |
| institution | Kabale University |
| issn | 2234-943X |
| language | English |
| publishDate | 2025-02-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj-art-aee118fa3adf4ee98dee676326c60b1a2025-02-06T05:21:41ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2025-02-011510.3389/fonc.2025.14996501499650Evaluation of patient immunocompetence for immune checkpoint inhibitor therapy using the psoas muscle index: a retrospective cohort studyToshiaki Tsurui0Toshiaki Tsurui1Toshiaki Tsurui2Toshiaki Tsurui3Kazuyuki Hamada4Emiko Mura5Risako Suzuki6Nana Iriguchi7Tomoyuki Ishiguro8Yuya Hirasawa9Ryotaro Ohkuma10Masahiro Shimokawa11Hirotsugu Ariizumi12Yutaro Kubota13Atsushi Horiike14Satoshi Wada15Satoshi Wada16Kiyoshi Yoshimura17Kiyoshi Yoshimura18Mayumi Tsuji19Yuji Kiuchi20Yuji Kiuchi21Takuya Tsunoda22Division of Medical Pharmacology, Showa University Graduate School of Medicine, Tokyo, JapanDepartment of Clinical Immuno-Oncology, Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa University, Tokyo, JapanDivision of Medical Oncology, Department of Medicine, Showa University School of Medicine, Tokyo, JapanPharmacological Research Center, Showa University, Tokyo, JapanDepartment of Chest Surgery, School of Medicine, Fukushima Medical University, Fukushima, JapanDepartment of Medical Oncology, Showa University Graduate School of Medicine, Tokyo, JapanDepartment of Medical Oncology, Showa University Graduate School of Medicine, Tokyo, JapanDepartment of Medical Oncology, Showa University Graduate School of Medicine, Tokyo, JapanDepartment of Medical Oncology, Showa University Graduate School of Medicine, Tokyo, JapanDepartment of Medical Oncology, Showa University Graduate School of Medicine, Tokyo, JapanDepartment of Medical Oncology, Showa University Graduate School of Medicine, Tokyo, JapanDepartment of Medical Oncology, Showa University Graduate School of Medicine, Tokyo, JapanDepartment of Medical Oncology, Showa University Graduate School of Medicine, Tokyo, JapanDepartment of Medical Oncology, Showa University Graduate School of Medicine, Tokyo, JapanDepartment of Medical Oncology, Showa University Graduate School of Medicine, Tokyo, JapanDepartment of Medical Oncology, Showa University Graduate School of Medicine, Tokyo, JapanDepartment of Clinical Diagnostic Oncology, Clinical Research Institute of Clinical Pharmacology and Therapeutics, Showa University, Tokyo, JapanDepartment of Clinical Immuno-Oncology, Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa University, Tokyo, JapanDepartment of Medical Oncology, Showa University Graduate School of Medicine, Tokyo, JapanPharmacological Research Center, Showa University, Tokyo, JapanDivision of Medical Pharmacology, Showa University Graduate School of Medicine, Tokyo, JapanPharmacological Research Center, Showa University, Tokyo, JapanDepartment of Medical Oncology, Showa University Graduate School of Medicine, Tokyo, JapanIntroductionIn patients with cancer, sarcopenia is an indicator of poor prognosis and is associated with an increased risk of chemotherapy-related adverse events. Skeletal muscle interacts with the immune system, and sarcopenia is associated with immune senescence. However, the association between sarcopenia and the response to immune checkpoint inhibitor (ICI) therapy remains unclear.MethodsThis retrospective study included patients with advanced or recurrent non-small cell lung cancer treated with nivolumab or pembrolizumab monotherapy. The association between the psoas muscle index (PMI) and both clinical response and immune-related adverse events (irAEs) was assessed using logistic regression. The PMI was calculated as the cross-sectional area of the psoas muscle divided by the square of the height based on computed tomography scans performed before the initial administration of ICI therapy.ResultsA total of 67 patients were included in the analysis. Logistic regression analysis showed that PMI was associated with the overall response (odds ratio [OR]: 1.52; 95% confidence interval [CI]: 1.04–2.22; p = 0.030) and the risk of severe irAEs (OR: 1.72; 95% CI: 1.05–2.80; p = 0.031).ConclusionThese findings suggest that PMI is both an indicator of prognosis and a surrogate marker of immunocompetence in predicting the clinical response to ICI therapy.https://www.frontiersin.org/articles/10.3389/fonc.2025.1499650/fullimmune checkpoint inhibitorsimmunotherapylung neoplasmssarcopeniaretrospective study |
| spellingShingle | Toshiaki Tsurui Toshiaki Tsurui Toshiaki Tsurui Toshiaki Tsurui Kazuyuki Hamada Emiko Mura Risako Suzuki Nana Iriguchi Tomoyuki Ishiguro Yuya Hirasawa Ryotaro Ohkuma Masahiro Shimokawa Hirotsugu Ariizumi Yutaro Kubota Atsushi Horiike Satoshi Wada Satoshi Wada Kiyoshi Yoshimura Kiyoshi Yoshimura Mayumi Tsuji Yuji Kiuchi Yuji Kiuchi Takuya Tsunoda Evaluation of patient immunocompetence for immune checkpoint inhibitor therapy using the psoas muscle index: a retrospective cohort study Frontiers in Oncology immune checkpoint inhibitors immunotherapy lung neoplasms sarcopenia retrospective study |
| title | Evaluation of patient immunocompetence for immune checkpoint inhibitor therapy using the psoas muscle index: a retrospective cohort study |
| title_full | Evaluation of patient immunocompetence for immune checkpoint inhibitor therapy using the psoas muscle index: a retrospective cohort study |
| title_fullStr | Evaluation of patient immunocompetence for immune checkpoint inhibitor therapy using the psoas muscle index: a retrospective cohort study |
| title_full_unstemmed | Evaluation of patient immunocompetence for immune checkpoint inhibitor therapy using the psoas muscle index: a retrospective cohort study |
| title_short | Evaluation of patient immunocompetence for immune checkpoint inhibitor therapy using the psoas muscle index: a retrospective cohort study |
| title_sort | evaluation of patient immunocompetence for immune checkpoint inhibitor therapy using the psoas muscle index a retrospective cohort study |
| topic | immune checkpoint inhibitors immunotherapy lung neoplasms sarcopenia retrospective study |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2025.1499650/full |
| work_keys_str_mv | AT toshiakitsurui evaluationofpatientimmunocompetenceforimmunecheckpointinhibitortherapyusingthepsoasmuscleindexaretrospectivecohortstudy AT toshiakitsurui evaluationofpatientimmunocompetenceforimmunecheckpointinhibitortherapyusingthepsoasmuscleindexaretrospectivecohortstudy AT toshiakitsurui evaluationofpatientimmunocompetenceforimmunecheckpointinhibitortherapyusingthepsoasmuscleindexaretrospectivecohortstudy AT toshiakitsurui evaluationofpatientimmunocompetenceforimmunecheckpointinhibitortherapyusingthepsoasmuscleindexaretrospectivecohortstudy AT kazuyukihamada evaluationofpatientimmunocompetenceforimmunecheckpointinhibitortherapyusingthepsoasmuscleindexaretrospectivecohortstudy AT emikomura evaluationofpatientimmunocompetenceforimmunecheckpointinhibitortherapyusingthepsoasmuscleindexaretrospectivecohortstudy AT risakosuzuki evaluationofpatientimmunocompetenceforimmunecheckpointinhibitortherapyusingthepsoasmuscleindexaretrospectivecohortstudy AT nanairiguchi evaluationofpatientimmunocompetenceforimmunecheckpointinhibitortherapyusingthepsoasmuscleindexaretrospectivecohortstudy AT tomoyukiishiguro evaluationofpatientimmunocompetenceforimmunecheckpointinhibitortherapyusingthepsoasmuscleindexaretrospectivecohortstudy AT yuyahirasawa evaluationofpatientimmunocompetenceforimmunecheckpointinhibitortherapyusingthepsoasmuscleindexaretrospectivecohortstudy AT ryotaroohkuma evaluationofpatientimmunocompetenceforimmunecheckpointinhibitortherapyusingthepsoasmuscleindexaretrospectivecohortstudy AT masahiroshimokawa evaluationofpatientimmunocompetenceforimmunecheckpointinhibitortherapyusingthepsoasmuscleindexaretrospectivecohortstudy AT hirotsuguariizumi evaluationofpatientimmunocompetenceforimmunecheckpointinhibitortherapyusingthepsoasmuscleindexaretrospectivecohortstudy AT yutarokubota evaluationofpatientimmunocompetenceforimmunecheckpointinhibitortherapyusingthepsoasmuscleindexaretrospectivecohortstudy AT atsushihoriike evaluationofpatientimmunocompetenceforimmunecheckpointinhibitortherapyusingthepsoasmuscleindexaretrospectivecohortstudy AT satoshiwada evaluationofpatientimmunocompetenceforimmunecheckpointinhibitortherapyusingthepsoasmuscleindexaretrospectivecohortstudy AT satoshiwada evaluationofpatientimmunocompetenceforimmunecheckpointinhibitortherapyusingthepsoasmuscleindexaretrospectivecohortstudy AT kiyoshiyoshimura evaluationofpatientimmunocompetenceforimmunecheckpointinhibitortherapyusingthepsoasmuscleindexaretrospectivecohortstudy AT kiyoshiyoshimura evaluationofpatientimmunocompetenceforimmunecheckpointinhibitortherapyusingthepsoasmuscleindexaretrospectivecohortstudy AT mayumitsuji evaluationofpatientimmunocompetenceforimmunecheckpointinhibitortherapyusingthepsoasmuscleindexaretrospectivecohortstudy AT yujikiuchi evaluationofpatientimmunocompetenceforimmunecheckpointinhibitortherapyusingthepsoasmuscleindexaretrospectivecohortstudy AT yujikiuchi evaluationofpatientimmunocompetenceforimmunecheckpointinhibitortherapyusingthepsoasmuscleindexaretrospectivecohortstudy AT takuyatsunoda evaluationofpatientimmunocompetenceforimmunecheckpointinhibitortherapyusingthepsoasmuscleindexaretrospectivecohortstudy |